Bonesupport AB¬†said Oct. 27 that it raised $37 million in equity and debt funding led by¬†Tellacq AB. Other investors included current shareholders such as¬†HealthCap,¬†Lundbeckfond Ventures,¬†Industrifonden,¬†AP3¬†(The Third Swedish National Pension Fund) and¬†Carl Westin. The debt finance was provided by¬†Kreos Capital. Bonesupport, of Lund, Sweden, provides products to treat patients with fractures and bone voids caused by trauma, infection, disease or related surgery.
BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that it has raised $37 million (SEK 327 million) in a combination of equity and debt finance. These new funds will be used to deliver further value from its unique CERAMENT platform. The oversubscribed equity financing was led by Tellacq AB and was supported by the Company‚Äôs current major shareholders, including HealthCap, Lundbeckfond Ventures, Industrifonden, AP3 (The Third Swedish National Pension Fund) and Carl Westin. The debt finance was provided by Kreos Capital.
Dr. H√•kan Bj√∂rklund of Tellacq AB will be joining the BONESUPPORT Board as Chairman in conjunction with the fund raising, subject to shareholder approval. Dr. Bj√∂rklund has a long and successful track record in the healthcare industry, including as the former CEO of Nycomed, which he grew from a small Scandinavian company into a global business before its acquisition by Takeda in 2011. He is currently chairman of the board of Swedish Orphan Biovitrum AB and an Industry Executive at Avista Capital Partners.
Richard Davies, CEO of BONESUPPORT said, ‚ÄúI am delighted that we have been able to complete this new financing to help us to execute our strategy to deliver the significant potential of our unique CERAMENT drug eluting osteoconductive/osteoinductive bioceramic platform. I am also pleased that the equity element reflects the significant progress that we have made during the course of 2016. With our sales on a strong growth trajectory, an increasing body of compelling clinical data and a drug eluting platform that will allow us to develop a pipeline of novel products to treat a broad range of bone diseases, BONESUPPORT can look to the future with great confidence.‚Äù
‚ÄúWe are delighted to welcome H√•kan Bj√∂rklund to the board at this exciting time for the company and look forward to benefiting from his extensive experience in the years ahead. I would also like to take this opportunity to thank the departing chairman Dr. √ñrn Stuge for his significant contribution to BONESUPPORT over many years‚Äù says Bj√∂rn Odlander, Managing Partner at HealthCap and board member.
H√•kan Bj√∂rklund, said: ‚ÄúOur decision to invest in BONESUPPORT was driven by the important progress that has been made over recent years. The CERAMENT drug eluting platform offers multiple opportunities to generate significant value by providing much needed and cost-efficient treatment options for patients with a broad range of bone diseases. I look forward to working with the management team and the Board to deliver BONESUPPORT‚Äôs potential to become a global leader in the management and treatment of bone disease. ‚Äù
The new funds will be used to support the execution of BONESUPPORT‚Äôs strategy to deliver significant shareholder value, focused on:
¬∑ Driving the sales of CERAMENT BVF, CERAMENT G and CERAMENT V in existing and new markets.
¬∑ Generating further clinical data to highlight the compelling benefits that the current CERAMENT products deliver and to conduct the FORTIFY study to support a planned PMA filing in the US for CERAMENT G.
¬∑ Building the Company‚Äôs product pipeline by capitalizing on the unique drug eluting properties of its injectable osteoconductive/osteoinductive bioceramic platform.
In the first half of 2016, BONESUPPORT‚Äôs overall sales have continued to grow rapidly driven by the European success of CERAMENT G and CERAMENT V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products are used for the management of problematic bone infections including osteomyelitis and prophylactically in patients who are at risk for developing infection. Sales of CERAMENT BVF have also shown good growth as the product has continued to gain traction in the US where it is marketed by BONESUPPORT‚Äôs partner Zimmer Biomet.
BONESUPPORT is also continuing to generate the clinical data needed to drive the adoption of its products. A recent paper in The Bone and Joint Journal 1 provided follow up data from the first 100 patients in a prospective study evaluating CERAMENT G for dead space (void) management in patients with chronic osteomyelitis (bone infection) using a single stage surgical procedure. These data showed that this approach, augmented by the use of CERAMENT G, was highly effective, delivering a 96% prevention of infection recurrence rate, a 3.0% fracture rate and a total wound leakage rate of 6.0%. This represents a significant improvement in both the infection recurrence and fracture rates when compared to published results evaluating alternative bone graft substitutes that deliver antibiotics locally.
The Company has also recently received approval from the US Food and Drug Administration (FDA) to begin an IDE (Investigational Device Exemption) study with CERAMENT G. The FORTIFY study, a randomized multicenter controlled trial, which will evaluate the safety and efficacy of CERAMENT G as part of surgical repair of open diaphyseal tibial fractures. The first patient is expected to be recruited into this prophylactic study before the end of 2016.
BONESUPPORT will also use the funds to develop its product pipeline. The Company believes that the attractive properties of its CERAMENT platform will allow it to develop products that will deliver a broad range of drugs to the bone to manage indications including osteoporosis, cancer and pain.
1) McNally et al, The Bone and Joint Journal, 2016, Vol. 98-B, No. 9, p1289-96
2) Raina, D. et al. A Biphasic Calcium Sulfate Hydroxapatite Carrier Bone Morphogenic Protein -2 and Zoledronic Acid Generates Bone (2016) Nature Scientific Reports